Ben Sasse was given a few months to live. He credits "providence, prayer and a miracle drug" for giving him more time. [CBS News]
Revolution Medicines (RVMD) had its price target raised by Leerink Partners from $147.00 to $171.00. They now have an "outperform" rating on the stock.
Revolution Medicines (RVMD) had its "buy" rating reaffirmed by HC Wainwright. They now have a $169.00 price target on the stock.
Revolution Medicines to Present Updated Phase 1/2 Clinical Data for Daraxonrasib in First Line Metastatic Pancreatic Cancer Across Monotherapy and Combination Cohorts at the 2026 AACR Annual Meeting
Revolution Medicines to Present Preclinical Data on Innovative Mutant-Targeted Catalytic RAS(ON) Inhibitor at the 2026 AACR Annual Meeting